Silvio Manfredo Vieira, PhD

Associate Research Scientist-Immunobiology

Departments & Organizations

Kriegel Lab


My work has focused on immunology, pharmacology and the study of autoimmune diseases. Autoimmune diseases are a broad range of related diseases in which a person’s immune system produces an inappropriate response against its own cells, tissues and/or organs, resulting in inflammation and damage. There are over 80 different autoimmune diseases, and these range from common to very rare diseases. I am best known for my research on rheumatoid arthritis, multiple sclerosis and systemic lupus erythematous.

A major aim of my current studies is to characterize the gastrointestinal microbiome of both mice and humans with systemic autoimmune diseases, and to potentially prove causal relations with humanized gnotobiotic animals. Moreover, my current project evaluate how gut commensal bacteria can translocate to the liver of patients with lupus and autoimmune hepatitis and cause inflammation. The ultimate goal is to develop novel biomarkers and therapeutic strategies for human autoimmune diseases.

Summary of Top Achievements:

  • Characterized the chemokine (C-X-C motif) receptor 2 (CXCR2) and its role in macrophage and mast cell activation, as well as neutrophil recruitment. I was the first researcher to show evidence implicating that CXCR2 in mast cells contributes to neutrophil recruitment.
  • Proved that gut commensal bacteria in the gastrointestinal tract, or translocated to the liver and secondary lymphoid tissues, influence the development of autoimmunity.
  • Determined that therapeutic vaccination with IL-27-conditioned dendritic cells suppressed established relapsing-remitting experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.
  • Described the pivotal role of the IL-17 signaling in the onset of experimental arthritis.
  • Verified that suppression of IL-33R expression in neutrophils, prevents IL-33-induced neutrophil migration, and is an important mechanism of anti-TNFα therapy of inflammation on rheumatoid arthritis.
  • Developed the first intramuscular vaccine approach to treat autoimmune diseases by targeting a gut commensal (Provisional Patent 047162-5229-P1-US.605947).

Education & Training

PhD University of Sao Paulo, Immunopharmacology (2009)

Honors & Recognition

  • Recognition e-poster - Gut Microbiota Modulation of Host Physiology: The Search for MechanismKeystone Symposia (2015)

  • Human and Translational ImmunologyYale University (2014)

  • Award Federation of Clinical Immunology Societies (FOCIS)FOCIS (2014)

  • The Jose Ribeiro do Valle / Eli Lilly Prize for Outstanding work in Pharmacology, Brazilian Society for Pharmacology and Experimental Therapeutics (SBFTE).Eli Lilly / SBFTE (2009)

  • Best research in Clinical ImmunologyBrazilian Society Federation for Experimental Biology (FeSBE) (2009)

  • XXXIII Congress of the Brazilian Society for Immunology (SBI), best scientific article presented by doctoral student.SBI (2008)

  • Best scientific work in inflammation presented by Ph.D. student.Brazilian Society for Pharmacology and Experimental Therapeutics (SBFTE) (2008)

  • Atem&remeR 1st Prize in InnovationSBFTE (2008)

  • Synthetic and Viral-based Gene SilencingSIGMA-ALDRICH CO. (2008)

  • Outstanding work in PharmacologyFAPEAM Foundation (2007)

  • Best scientific work in immunopharmacology presented by M.Sc. student.Brazilian Society for Pharmacology and Experimental Therapeutics (SBFTE) (2006)

  • Long-Term fellowship.FAPEAM Foundation (2006)

  • Award for M.Sc best research in InflammationBrazilian Society Federation for Experimental Biology (FeSBE) (2005)

  • Long-Term fellowship.FAPEAM Foundation (2004)

Professional Service

  • Office of International Students and Scholars (OISS) - Yale University (2015 - Present) Brazil Ambassador at Yale


  • A Pathogenic Role for the Gut Microbiota in Antiphospholipid Syndrome and Lupus United States (2014 - 2014)

  • Selective Targeting of the Gut Microbiota with Single Antibiotics Prevents Mortality in the Autoimmune-prone (NZWxBXSB)F1 Model United States (2014 - 2014)

  • Depletion of the Gut Microbiome Prevents both Lupus Nephritis and Antiphospholipid Syndrome-associated Mortality in the (NZWxBXSB)F1 Model United States (2014 - 2014)

  • The intracellular pattern recognition receptor NOD2 is crucial for development of arthritis. Brazil (2009 - 2009)

  • The intracellular pattern recognition receptor NOD-2 is involved in the process of the inflammatory response in arthritis. Brazil (2008 - 2008)

Edit this profile

Contact Info

Silvio Manfredo Vieira, PhD
Mailing Address
10 Amistad Street
New Haven, CT 06509
Diet, microbiota and autoimmune diseases
Research Image 3